Diet-induced obesity and mammary tumor development in MMTV-neu female mice
Diet-induced obesity and mammary tumor development in MMTV-neu female mice
复制标题
DOI：
10.1207/s15327914nc5002_7
复制
发表时间：
2004-01-01
影响因子：
2.9
通讯作者：
Maihle, NJ
中科院分区：
文献类型：
--
作者：
Cleary, MP;Grande, JP;Maihle, NJ
肥胖是绝经后乳腺癌的一个危险因素，与动物中潜伏期缩短和/或乳腺肿瘤（MT）发病率增加有关。体重增加通常与肿瘤反应性相关。与这些数据一致，我们先前表明，饮食诱导肥胖的MMTV-TGF-α小鼠中的MMTV-TGF-α反应性MT的潜伏期显著缩短。在这里，我们使用相同的协议，以确定饮食诱导的肥胖对雌激素受体阴性MT的发展MMTV-neu（株202）小鼠的影响。小鼠从10周龄开始喂食低脂饮食（n = 20）或高脂饮食（n = 54）。19周龄时的体重用于将高脂肪小鼠分配到肥胖倾向组、超重组和肥胖抵抗组。由于MT大小或在85周龄时对小鼠实施安乐死。肥胖倾向小鼠的最终体重最重，而肥胖抵抗组和低脂组的最终体重相似。脂肪垫重量在肥胖倾向小鼠中最重，其次是超重和肥胖抵抗组，而在低脂小鼠中最轻。低脂肪和高脂肪小鼠的血清IGF-I水平相似，而高脂肪小鼠的瘦素水平较高（P < 0.0001）。所有组的MT潜伏期、发病率、转移和负荷相似。这些发现支持肥胖不是雌激素阴性乳腺癌发展的危险因素。
Obesity is a risk factor for postmenopausal breast cancer and is associated with shortened latency and/or increased mammary tumor (MT) incidence in animals. Elevated body weight is usually associated with hormone-responsive tumors. In agreement with these data we previously showed that latency of hormone-responsive MTs in MMTV-TGF-alpha mice with diet-induced obesity was significantly shortened. Here, we used the same protocol to determine the impact of diet-induced obesity on estrogen receptor-negative MT development in MMTV-neu (strain 202) mice. Mice were fed a low-fat diet (n = 20) or a high-fat diet (n = 54) from 10 wk of age. Body weight at 19 wk of age was used to assign high-fat mice to obesity-prone, overweight, and obesity-resistant groups. Mice were euthanized due to MT size or at 85 wk of age. Final body weights of obesity-prone mice were heaviest, and those of obesity-resistant and low-fat groups were similar Fat pad weights were heaviest in obesity-prone mice followed by overweight and obesity- resistant groups, and lightest in low-fat mice. Serum IGF-I levels were similar for low-fat and high-fat mice, whereas leptin was higher in high-fat mice (P < 0.0001). MT latency, incidence, metastasis, and burden were similar for all groups. These findings support that obesity is not a risk factor for development of estrogen-negative breast cancer.